SS
AKRO

Steve Schonfeld’s Akero Therapeutics AKRO Stock Holding History

Steve Schonfeld’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-303,814
Closed -$14.4M – 2015
2025
Q3 		$14.4M Buy
303,814
+162,508
+115% +$7.87M 0.08% 261
2025
Q2 		$7.54M Sell
141,306
-172,625
-55% -$7.84M 0.05% 421
2025
Q1 		$12.7M Buy
313,931
+51,636
+20% +$2.19M 0.08% 259
2024
Q4 		$7.3M Sell
262,295
-16,028
-6% -$485K 0.04% 392
2024
Q3 		$7.99M Sell
278,323
-163,471
-37% -$4.26M 0.05% 365
2024
Q2 		$10.4M Sell
441,794
-253,929
-36% -$5.43M 0.07% 339
2024
Q1 		$17.6M Buy
695,723
+561,371
+418% +$13.5M 0.12% 203
2023
Q4 		$3.14M Sell
134,352
-77,656
-37% -$1.53M 0.02% 656
2023
Q3 		$10.7M Buy
212,008
+36,808
+21% +$1.71M 0.08% 328
2023
Q2 		$8.18M Buy
175,200
+115,522
+194% +$5.29M 0.07% 390
2023
Q1 		$2.28M Sell
59,678
-38,478
-39% -$1.72M 0.02% 656
2022
Q4 		$5.38M Buy
98,156
+89,256
+1,003% +$3.82M 0.04% 457
2022
Q3 		$303K Sell
8,900
-15,000
-63% -$230K ﹤0.01% 2072
2022
Q2 		$225K Buy
+23,900
New +$249K ﹤0.01% 1826

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Steve Schonfeld's AKRO Position: Q4 2025 in Review

Steve Schonfeld sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 303,814 shares — an estimated $14.4M sold.

Steve Schonfeld first reported a position in AKRO in Q2 2022 and held it in 14 quarters. The position peaked at $17.6M in Q1 2024. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Steve Schonfeld reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Steve Schonfeld sold 303,814 Akero Therapeutics shares in Q4 2025, an estimated $14.4M.
  • Steve Schonfeld first reported a position in Akero Therapeutics in Q2 2022 and held it in 14 quarters.
  • Steve Schonfeld's Akero Therapeutics position peaked at $17.6M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.